Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1523-1747.ep13077204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Facial demodicosis in the immunosuppressed state: a retrospective case series from a tertiary referral center.
Int J Dermatol
October 2022
Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
Background: Data on Demodex in the immunosuppressed state is limited, focusing mainly on patients with human immunodeficiency virus and hematological malignancies. The aim of this study was to describe the manifestations of facial demodicosis in diverse immunosuppressive states.
Methods: The medical records of all patients followed at a Demodex outpatient clinic of a tertiary medical center from January 2008 to November 2020 were retrospectively reviewed.
Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease.
Am J Otolaryngol
January 2022
Department of Otolaryngology - Head and Neck Surgery, Medical College of Georgia - Augusta University, Augusta, GA, USA.
Background: Chronic rhinosinusitis (CRS) in the setting of Aspirin Exacerbated Respiratory Disease (AERD) have high rate of treatment failure and disease recurrence.
Objective: Evaluate the long-term effect of zileuton on sinonasal outcomes in patients with AERD.
Methods: AERD patients were reviewed and divided into two cohorts, depending if they were treated with zileuton during their clinical course.
Hydroxyurea-induced genital ulcers and erosions: Two case reports.
J Tissue Viability
August 2021
Harvard Medical School, Boston, MA, USA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA. Electronic address:
Hydroxyurea is a chemotherapeutic agent used for myeloproliferative disorders and sickle cell anemia that is well known to cause painful mucocutaneous ulcers, typically involving the legs or mouth. However, genital ulcerations due to hydroxyurea therapy are a rare, and likely underrecognized, adverse effect with only a few cases reported in the literature to date. Ulcers of the lower legs caused by hydroxyurea are associated with a diagnostic delay, and this is likely exacerbated in cases of genital ulceration due to a lack of awareness.
View Article and Find Full Text PDFImportance: Although effective agents are available to prevent painful vaso-occlusive episodes of sickle cell disease (SCD), there are no disease-modifying therapies for ongoing painful vaso-occlusive episodes; treatment remains supportive. A previous phase 3 trial of poloxamer 188 reported shortened duration of painful vaso-occlusive episodes in SCD, particularly in children and participants treated with hydroxyurea.
Objective: To reassess the efficacy of poloxamer 188 for vaso-occlusive episodes.
Hydroxyurea-induced superinfected ulcerations: Two case reports and review of the literature.
Exp Ther Med
December 2020
Dermatology Department, Faculty of Medicine, University Lucian Blaga of Sibiu, 550169 Sibiu, Romania.
The chronic use of hydroxyurea (HU) in some oncologic and non-oncologic diseases (psoriasis, sickle cell anemia) can be accompanied by side effects, both systemic and mucocutaneous. The most severe adverse events known in HU therapy are leg ulcers and cutaneous carcinomas. At skin level may also appear: xerosis, persistent pruritus, skin color changes (erythema, hyperpigmentation), cutaneous atrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!